0001209191-21-063007.txt : 20211104
0001209191-21-063007.hdr.sgml : 20211104
20211104191423
ACCESSION NUMBER: 0001209191-21-063007
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211103
FILED AS OF DATE: 20211104
DATE AS OF CHANGE: 20211104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Pang Phillip
CENTRAL INDEX KEY: 0001787370
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39083
FILM NUMBER: 211381742
MAIL ADDRESS:
STREET 1: C/O VIR BIOTECHNOLOGY, INC.
STREET 2: 499 ILLINOIS STREET, SUITE 500
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vir Biotechnology, Inc.
CENTRAL INDEX KEY: 0001706431
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 812730369
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 499 ILLINOIS STREET
STREET 2: SUITE 500
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
BUSINESS PHONE: 415-906-4324
MAIL ADDRESS:
STREET 1: 499 ILLINOIS STREET
STREET 2: SUITE 500
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-11-03
0
0001706431
Vir Biotechnology, Inc.
VIR
0001787370
Pang Phillip
C/O VIR BIOTECHNOLOGY, INC.
499 ILLINOIS STREET, SUITE 500
SAN FRANCISCO
CA
94158
0
1
0
0
Chief Medical Officer
Common Stock
2021-11-03
4
M
0
5000
5.175
A
105277
D
Common Stock
2021-11-03
4
S
0
5000
36.4661
D
100277
D
Stock Option (Right to Buy)
5.175
2021-11-03
4
M
0
5000
0.00
D
2029-03-10
Common Stock
5000
47129
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.22 to $36.76 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
1/4 of the shares subject to the stock option vested and became exercisable on March 11, 2020, and the remaining shares will vest in 36 equal monthly installments thereafter.
/s/ Howard Horn, Attorney-in-Fact
2021-11-04